Brian W Ogilvie, Ph.D. - Sekisui XenoTech, LLC - Director of Consulting

Brian W Ogilvie

Ph.D.

Sekisui XenoTech, LLC

Director of Consulting

Kansas City, KS | USA

Additional Specialties: In vitro ADME, CYP inhibition, drug transporters

ORCID logohttps://orcid.org/0000-0001-7581-893X

Brian W Ogilvie, Ph.D. - Sekisui XenoTech, LLC - Director of Consulting

Brian W Ogilvie

Ph.D.

Introduction

Primary Affiliation: Sekisui XenoTech, LLC - Kansas City, KS , USA

Additional Specialties:

Research Interests:

Education

May 2015
University of Kansas Medical Center
Ph.D.
Pharmacology, Toxicology and Therapeutics

Experience

Mar 1997
Sekisui XenoTech LLC
Vice President
Consulting

Publications

16Publications

517Reads

1Profile Views

75PubMed Central Citations

An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.

Drug Metab Dispos 2018 Aug 7;46(8):1066-1074. Epub 2018 May 7.

Sekisui XenoTech LLC, Kansas City, Kansas (F.K., P.Y., C.M., D.B.B., B.W.O.); Janssen Research & Development LLC, Spring House, Pennsylvania (F.K.); XPD Consulting, Shawnee, Kansas (A.P.); and Roivant Sciences, Durham, North Carolina (D.B.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.118.081729DOI Listing
August 2018
13 Reads
3.252 Impact Factor

The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments.

Drug Metab Dispos 2015 Nov 9;43(11):1744-50. Epub 2015 Sep 9.

XenoTech, LLC, Lenexa, Kansas (L.J.H., F.K., B.W.O., D.B.B., B.D.S., S.L.); and XPD Consulting, Shawnee, Kansas (B.P., O.P., A.P.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.066597DOI Listing
November 2015
8 Reads
1 Citation
3.252 Impact Factor

Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.

J Clin Pharmacol 2015 Sep 7;55(9):1004-11. Epub 2015 May 7.

Vanda Pharmaceuticals, Inc., Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.507DOI Listing
September 2015
6 Reads
1 Citation

Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: a case study example with the prodrug ceftobiprole medocaril.

J Pharm Sci 2012 Mar 17;101(3):1242-52. Epub 2011 Nov 17.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey 08869, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.22816DOI Listing
March 2012
99 Reads
1 Citation
2.590 Impact Factor

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.

Drug Metab Dispos 2011 Nov 27;39(11):2020-33. Epub 2011 Jul 27.

XenoTech, LLC, 16825 West 116th Street, Lenexa, KS 66219, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.111.041293DOI Listing
November 2011
9 Reads
7 Citations
3.252 Impact Factor

An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes.

Drug Metab Dispos 2011 Aug 27;39(8):1370-87. Epub 2011 Apr 27.

XenoTech, LLC, Lenexa, KS 66219, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.111.038596DOI Listing
August 2011
25 Reads
2 Citations
3.252 Impact Factor

Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments.

Drug Metab Dispos 2011 Jun 7;39(6):1031-8. Epub 2011 Mar 7.

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.110.036129DOI Listing
June 2011
23 Reads
6 Citations
3.252 Impact Factor

Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4.

Drug Metab Dispos 2009 Oct 23;37(10):2103-11. Epub 2009 Jul 23.

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.109.027193DOI Listing
October 2009
60 Reads
4 Citations
3.252 Impact Factor

In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.

Drug Metab Dispos 2009 Oct 16;37(10):2045-54. Epub 2009 Jul 16.

XenoTech LLC, Lenexa, KS 66219, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.109.028274DOI Listing
October 2009
120 Reads
8 Citations
3.252 Impact Factor

Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.

Toxicol In Vitro 2006 Mar;20(2):154-62

Portola Pharmaceuticals, 270 East Grand Ave. South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tiv.2005.06.047DOI Listing
March 2006
47 Reads
7 Citations
2.903 Impact Factor

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.

Drug Metab Dispos 2006 Jan 18;34(1):191-7. Epub 2005 Nov 18.

XenoTech, LLC, 16825 West 116 Street, Lenexa, KS 66219, USA.

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.105.007633
Publisher Site
http://dx.doi.org/10.1124/dmd.105.007633DOI Listing
January 2006
49 Reads
25 Citations
3.252 Impact Factor

Biotransformation of the anti-angiogenic compound SU5416.

Drug Metab Dispos 2000 Dec;28(12):1505-12

SUGEN, Inc., South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
December 2000
2 Reads
2 Citations
3.252 Impact Factor

Top co-authors

Andrew Parkinson
Andrew Parkinson

Graduate School of Pharmaceutical Sciences

13
David B Buckley
David B Buckley

University of Kansas Medical Center

6
Faraz Kazmi
Faraz Kazmi

XenoTech

5
Brandy L Paris
Brandy L Paris

XenoTech LLC

5
Phyllis Yerino
Phyllis Yerino

XenoTech

4
Paul Toren
Paul Toren

University of Toronto

3
Yuichi Sugiyama
Yuichi Sugiyama

Sugiyama Laboratory

2
Florence Ndikum-Moffor
Florence Ndikum-Moffor

University of Kansas Medical Center

2